FIG 2 .
Screening novel LSD1 inhibitors identifies lead compounds with improved potency in the repression of HSV-1 IE gene expression. (A) Structures of TCP, OG-L002, clorgyline (CLG), and safinamide (SAF). IC50s were determined in vitro for monoamine oxidase-A/B (MAO-A/B), monoamine oxidase-B (MAO-B), and LSD1. (B) Inhibition of LSD1 in vitro by TCP and OG-L002 is graphically represented. (C) HeLa cells were pretreated for 5 h with DMSO control or the indicated compound (50 µM) followed by infection with HSV-1 (0.1 PFU/cell) for 2 h. The levels of viral immediate-early (ICP4 and ICP27) and cellular control (S15) mRNAs were determined by qRT-PCR and are expressed as ratios to the levels in control DMSO-treated cells. OG-L002 and clorgyline were selected for further comparative analyses.